Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003279 · ClinicalTrials.gov registry record · Phase 3
Vaccination Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
A Phase 3 study, sponsored by European Organisation for Research and Treatment of Cancer - EORTC.
- Completed
- Registry status
- Phase 3
- Development phase
- 500
- Enrollment target
NCT00003279 is a Phase 3 study that has completed, run by European Organisation for Research and Treatment of Cancer - EORTC. The registered enrollment target is 500 participants.
The verdict
NCT00003279, a Phase 3 study, has completed, sponsored by European Organisation for Research and Treatment of Cancer - EORTC.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 500 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines may help the body build an immune response to kill tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of vaccination with monoclonal antibody BEC2 and BCG with that of no further therapy in treating patients who have limited-stage small cell lung cancer.
Interventions
- BIOLOGICAL BCG vaccine
- BIOLOGICAL monoclonal antibody BEC2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 1998-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003279
The ClinicalTrials.gov registry entry for NCT00003279 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is European Organisation for Research and Treatment of Cancer - EORTC, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BCG vaccine is the first listed.
NCT00003279 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003279 about?
NCT00003279 is a clinical study titled "Vaccination Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer". RATIONALE: Vaccines may help the body build an immune response to kill tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of vaccination with monoclonal antibody BEC2 and BCG with that of no further therapy in treating patients who have limited-stage small cell lung cance...
What is the current status of trial NCT00003279?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 500 participants. The study started on 1998-03.
What interventions are being tested in trial NCT00003279?
The interventions under investigation include: BCG vaccine (BIOLOGICAL), monoclonal antibody BEC2 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003279?
This trial is sponsored by European Organisation for Research and Treatment of Cancer - EORTC, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.